The Shared Decision-Making Process in the Pharmacological Management of Depression

Malcom Hopwood

Published online: 23 September 2019
© The Author(s) 2019

Abstract

Shared decision making (SDM) is a model of interaction between doctors and patients in which both actors contribute to the medical decision-making process. There is an international consensus across medicine about the importance of SDM interventions, which have raised great interest in mental healthcare over the last decade. Yet SDM is not widely adopted, particularly in the field of psychiatry. The purpose of the present article is to examine, from a patient and physician perspective, the importance of SDM in the management of healthcare with a focus on mental health; it reviews the enablers and barriers (and how to overcome them) to implementing a SDM process in psychiatric practice. SDM models have been developed recently for involving patients with depression in the decision-making process, which could result in augmenting the proportion of patients who adhere to their antidepressant or other treatments for a duration that complies with the current recommendations. To implement this approach, more physicians need training in the SDM approach and access to appropriate tools that help engage in collaborative deliberation, and practice generally needs to be reorganized around the principles of patient engagement.

Key Points for Decision Makers

- Models of shared decision making (SDM) are not widely adopted in psychiatric practice.
- SDM may help improve adherence to antidepressant medication.
- Physicians need training in practicing an SDM process with patients with depression.

1 Key Features of Depression Treatment

Major depressive disorder (MDD) is a complex, heterogeneous, and potentially long-term condition that gives rise to serious handicaps and disabilities [1]. Following a stepped approach in depression care, the physician may start prescribing nonpharmacological therapies [2, 3] before proceeding to pharmacological treatments that can effectively mitigate the burden of depression, though this approach is sometimes subject to controversy [4, 5]. Treatment guidelines recommend continuous use of antidepressants for several months to reach and maintain remission, but this is far from being achieved in current practice [6]. In everyday medical practice, the efficacy of antidepressants is reduced by low patient adherence rates and premature discontinuation, which contribute to an increased risk of relapse [7–10] and the chance of developing a chronic disease and increased morbidity and mortality. In fact, only a limited proportion of patients sufficiently adhere to their treatment [11, 12], which may be related to several factors. First, patients organize their drug intake around their own priorities, which may be very different from prescribers’ priorities, since most patients value their personal concerns and/or their social roles more than the benefits of a prescribed treatment. Second, factors associated with early discontinuation of antidepressant treatment include stigma and patient skepticism toward treatment [13, 14]. Patients are reluctant to start antidepressants because of the fear that it can be difficult to withdraw from every psychotropic drug [12]. Third, patients are generally aware...
of the side effects of antidepressant medications but do not necessarily distinguish the differences between drug classes [15]. Typically, there is a reluctance to start or continue antidepressants because patients have either developed side effects or believe they will. As long-term adherence to antidepressant treatment is primarily determined by the balance between the perceived necessity and perceived harmfulness of the medication [13, 14], tolerability becomes an increasingly important factor, with a longer duration of treatment as depressive symptoms recede [12]. It is important that clinicians present this information to patients in meaningful ways [16, 17]. Fourth, another factor is the absence of a perceived clinical benefit during the initial stages of treatment, as the efficacy of most antidepressant drugs against depressive symptoms generally builds over several weeks. Clinicians are advised to inform patients of the likely delayed onset of a perceived benefit of antidepressant drugs [18].

All these factors were reported in a clinical audit (TAILOR [Target Antidepressant Initiation choice to unLock positive patient Outcomes and Response]) involving 7650 patients and 1873 general practitioner clinics in Australia (data on file; results represent findings collected up to June 2018). Importantly, most patients had concerns about starting antidepressant treatment because of possible side effects, the most frequently mentioned being weight gain, sleep disturbance, and sexual dysfunction. This audit identified the importance of involving the patient in the decision-making process; once the treatment options were presented, the patient could share the decision on what management to follow. Clearly, targeted and tailored communication offers promise for fomenting discussion and reducing barriers to an appropriate initial treatment of depression.

A gap sometimes exists between patients’ views and professionals’ views, a gap mainly related to the patients’ health beliefs and the physicians’ attitudes. What depressed patients consider important in defining remission from depression may differ from what a physician sees as important [19, 20]. In a survey involving 535 psychiatric outpatients treated for MDD, the three items most frequently judged by the patients to be very important in determining remission were the presence of features of positive mental health, such as optimism and self-confidence, a return to their usual, normal self, and a return to their usual level of functioning. The patients endorsed a statement about absence of symptoms with nearly similar frequency [20].

It is critical to improve the process by which patients and clinicians together select and implement antidepressants; it should augment the proportion of patients who adhere to their antidepressant treatment for a duration that complies with the current recommendations.

2 Shared Decision Making (SDM): Findings from Somatic Medicine

The number of patients who discontinue drug therapy prematurely can be lowered when patients can decide which treatment they prefer [21]. Alternatively, the research has documented that lack of patient information, problems within the doctor–patient communication, and low patient participation in the medical decision-making process are key predictors of patient reluctance to engage in or continue with treatment [22, 23].

Models of shared decision making (SDM) have been developed as a strategy for involving patients in the decision-making process, which could result in improved clinical outcomes. SDM approaches emerged as a reaction to medicine’s traditional “ paternalism,” wherein physicians exercise the dominant role in treatment decision making [24]. SDM is a collaborative process in which clinicians and patients work together to reach a consensus about treatment or diagnostic decisions; it is a process whereby clinicians present patients with technical information regarding the disease (diagnosis, etiology, prognosis) and the benefits and risks of the available treatment options and patients inform clinicians about their beliefs, values, goals, experiences, and preferences about the consequences of those treatment options. SDM involves the provision of evidence-based information about options, outcomes, and uncertainties, together with decision-support counseling and a system for recording and implementing patients’ “informed preferences” [25]. Bringing these two types of expertise together should produce better decisions. SDM is especially relevant (1) when there is more than one reasonable option, (2) when the scientific evidence about the effectiveness or safety of available treatments is scarce, (3) when treatments show a similar balance between benefits and risks, or (4) when possible benefits and harms of each option affect patients differently.

Overall, there is international consensus across medicine about the importance of SDM, and it is widely supported [26]. Policy makers may perceive SDM as desirable because of its potential to (1) reduce overuse of options not clearly associated with benefits for all; (2) enhance the use of options clearly associated with benefits for the vast majority; (3) reduce unwarranted healthcare practice variations; and (4) promote the right of patients to be involved in decisions concerning their health.

SDM interventions have been successfully implemented when treating various illnesses, such as breast and prostate cancer [27]. Patients have shown reduced psychological distress and improved functioning [28, 29], and they have achieved better health outcomes when perceiving themselves as more involved in the decision-making process.
3 The Importance of SDM in Mental Healthcare

Following beneficial applications of SDM in caring for physical illnesses [34], researchers have incorporated principles and elements of SDM for different mental health interventions. In this field, SDM is associated with enhanced patient satisfaction, adherence, empowerment, and guideline-concordant care [23, 35–37].

SDM interventions have been developed for depressed individuals [31, 38–42]. Loh et al. [23] found that, after an SDM intervention, depressed primary care patients displayed significantly greater participation in decision making and greater treatment satisfaction. A systematic review [43] identified 11 randomized controlled trials, including one focusing on depression [44]. Five trials, including the two mental health trials, showed positive outcomes associated with SDM, but the reviewers concluded that the overall evidence was encouraging but inconclusive. SDM can lead to reduced substance use and improved quality of life [45], and is associated with increased patient autonomy [46]. In a systematic literature review, Samalin et al. [47] identified three 6-month studies demonstrating that SDM interventions using decision aids effectively improved depressed patients’ satisfaction and engagement in the decision-making process. Regarding treatment adherence or reduced depression severity, results remain inconclusive [23], but the clinician–patient alliance and communication can be associated with improved antidepressant treatment adherence [48, 49]. Studies comparing the effects of SDM with usual care on patient adherence in mental disorders are ongoing [50].

4 Implementing an SDM Process in Mental Health

4.1 Patient and Physician Roles

Patients increasingly expect, as a right, to be active participants in decisions about the management of their disease; for many patients, the time spent meeting with their physician—the clinical encounter—is the most opportune moment for them to become engaged in their own health through the process of SDM. The patient’s point of view was gathered through the testimony of a patient advocate (see Box 1), who considers SDM a win–win relationship, an intervention to be systematically implemented as it helps improving adherence to medication by alleviating patients’ fears. Most patients with mental disorders wish to be involved in the decision-making process [39, 51, 52]. Most patients, including depressed individuals, welcome information about a wide range of topics, including their medical condition and pertinent treatments [40, 53, 54]; side effects of medications are of special interest for patients [37]. Patients with depressive disorders desire an active participation in the decision-making process [55], meaning they are more likely to take an active role in the process than patients with mild forms of hypertension, heart disease, and severe diabetes [56].

Studies of individuals experiencing severe mental illnesses have found that (1) most patients desire a greater participation in treatment decisions; (2) greater personal experience living with the illness is associated with greater desire for such involvement; and (3) most patients participate in SDM interventions when offered the opportunity [57, 58].

Clinicians can clarify the patient’s understanding and make or explicitly defer a decision [59]. After initiation of the treatment, frequent patient–physician contacts may increase the probability that patients will continue therapy in the long term [22].

4.2 Common Misconceptions

There are several common misconceptions about using an SDM process in patients with depression. The first is that physicians may experience time and cost constraints. An in-depth assessment of needs that considers the patients’, relatives’, and experts’ views is expected to be a highly time- and cost-consuming process. Most physicians failed to use the SDM process when consulting patients with depression, and they tended to “treat first and involve patients later” and felt that discussing differences among the choice of medications was not a good use of time [60]. However, the SDM process follows a usual consultation in depression and is not believed to add cost or extend more than a few minutes to the time needed for the consultation [61–63].

A second misconception is that “the patient feels unsupported if left to decide,” but the SDM process is clearly a shared activity, and it must be emphasized that the decision will be made together.

Third, some healthcare professionals express doubts, saying that patients do not want to be involved in decisions. As noted, most depressed patients wish to actively participate in treatment decision making and generally want more involvement than patients with other general medical problems. Of course, some patients may prefer that their physician alone select the appropriate intervention; thus, older, less educated, and physically sicker
patients typically prefer less active roles in the decision-making process [64–67] to minimize anxiety associated with the process.

Finally, physicians sometimes claim they are “already using the SDM approach,” but there is evidence to the contrary [68–70]. Evidence suggests that physicians performed poorly on standardized measures of the SDM process, such as the OPTION scale (“observing patient involvement”) [71]. In view of these misconceptions, it is clear that the first step for those advocating the uptake of SDM is to ensure that physicians support the underlying rationale.

4.3 Barriers to Practicing an SDM Process

There are barriers to practicing an SDM process in mental health. First, SDM involves a shift in power arrangements, so there is a challenge to the clinician’s autonomy and authority, particularly in the field of mental health. A study found that participants using psychiatric outpatient services said they were helped to understand the information but the selection of treatment was not a consensus decision [72]. It may become difficult for patients to support SDM if it apparently involves conversations always ending up with the clinician’s view prevailing [73]. It is important to identify and re-evaluate discrepant patient–clinician values and to provide patients with the skills, information, and motivation to participate equally and fully in the medical decision-making encounter [14, 52, 56, 64, 74]. Ideally, the physician should enable the patient to gain the following skills so the process is equitable: (1) how to ask questions about their condition and possible treatments; (2) how to seek out information; (3) how to evaluate information regarding treatment and decisions; (4) how to discuss treatment options with their physician, questioning the reasoning behind treatment decisions; and (5) how to communicate their needs, values, and preferences to physicians. This is, of course, time consuming and may add to the consultation time but would certainly be worth the effort.

As engaging in SDM may require knowledge, confidence, and high levels of health literacy, there may be a risk that SDM primarily attracts and benefits those who are natural information seekers, who are educated, empowered, and able to advocate for their needs, while marginalizing other patients. It therefore becomes essential to promote SDM by tailoring communication, information, and SDM interventions to the specific needs of traditionally disengaged individuals and by using tools and processes that are sufficiently accessible [75]. Clinicians may also find it difficult to access or communicate evidence, whereas patients may have a fear of being judged [76].

4.4 Overcoming Barriers

Barriers to implementing SDM can be overcome with a consistent approach and changes to practice processes. Changing practices involves the use of formal decision-support tools that may target behavior change in either clinicians or patients.

Decision aids are tools designed to educate patients about treatment options and help them make informed choices. These evidence-based interventions are designed to engage patients and clinicians in an SDM process and translate research evidence into patient-centered care [42, 77]. Materials have been developed in different formats, such as paper and pencil instruments, videos, audio-guided workbooks, web-based tools [78], and interactive software that can be used alone by the patient or in interaction with the healthcare professional. A consult decision-aid prototype was recently developed with evidence from Cochrane reviews [79]. Decision aids may also encourage patients to think about their personal values and preferences regarding the benefits and risks of the different treatment options and the influence these treatment options could have on their lives and well-being. Decision aids do promote SDM when used during the clinical encounter [80], and, in comparison with standard counseling, they can produce greater patient knowledge about treatment options and more realistic expectations about treatment, as well as increase the likelihood of receiving a treatment that is consistent with personal values [34, 81].

These approaches have been evaluated in depression, and they did help primary care clinicians and patients select antidepressants together that best fit with the patient’s values, preferences, and goals, improving the decision-making process, as well as patient participation and satisfaction without adding to the consultation time [23, 61].

5 Conclusion

Improving the process by which patients and clinicians together select and implement antidepressants should augment the proportion of patients who adhere to their antidepressant treatment for a duration that complies with the current recommendations. Treatment initiation and adherence stem from: (1) the reciprocal influences and interactions of individuals and healthcare professionals; (2) the degree to which participants agree about treatment goals and the methods for achieving them; (3) communication styles that actively engage both partners in a decision-making dialogue; (4) the individual’s belief that treatment is beneficial despite required effort, or even possible negative consequences (side effects); and (5) the individual’s confidence in their ability
to initiate, pursue, and follow through with the treatment regimen.

For depressed individuals, it is important to improve the frequency of SDM because it respects patient autonomy and promotes patient engagement and empowerment in a manner directly relevant to the helplessness and hopelessness intrinsic to depression. SDM may indirectly improve clinical outcomes because there is some evidence that, when patients have made well-informed decisions, they also adhere to their medication better and receive guideline-concordant treatment [43, 47]. Finally, more physicians need training in the approach by having access to appropriate tools that help them engage in collaborative deliberation, and more practices need to be reorganized around the principles of patient engagement.

Compliance with Ethical Standards

Conflict of interest Prof. Malcom Hopwood has served as a board member for Phoenix and the Royal Australian and New Zealand College of Psychiatrists, Summer Foundation; received speaker’s fees/honoraria from Eli Lilly, Health Ed, Janssen-Cilag, Lundbeck, Psych Scene, and Servier; served on advisory boards or provided consultancy for Lundbeck and Servier; received travel support from Bionomics, Eli Lilly, Janssen-Cilag, Lundbeck, and Servier; and received clinical trial/research support from Bionomics, ISSCR, Lundbeck, NHMRC, Ramsay Health Foundation, Servier, VNI, and the Weary Dunlop Foundation.

Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Box 1: Interview of Mrs C., a French patient advocate and patient teacher

Why are patients reluctant to follow a pharmacological treatment plan?

Mrs C.: “When speaking about nonadherence to a pharmacological treatment, we often think of the fear of adverse effects, skepticism toward therapeutic efficacy, and the fear of addiction. These are not the only issues; for example, taking a medicine also reminds you of your illness daily, which can prevent you from living normally. Patients stop taking the treatment as they feel better.”

What is the priority for patients to adhere to treatment?

Mrs C.: “SDM is one of the priority solutions allowing patients to adhere to treatments. Both the patient and the doctor get involved in decision making and negotiate for the best option. We negotiate all the time; why not with our doctor? When the doctor and the patient make a mutual agreement, the patient is more engaged. The SDM process holds clear benefits for patients who become an actor in their own treatment; they decide together and are more committed. There are also benefits for the doctor who can better know the patients and engage in a true partnership based on communication; it’s a win–win relationship. Of course, there will probably be a longer consultation time to achieve agreement between the two parties, but this is worth it.”

Do patients want to be more involved?

Mrs C.: “All patients want to be involved. Doctors often inform patients of the benefits, the risks, the therapeutic options, … and the clinician’s view prevails at the end. In the SDM process, information and decisions are shared. The difficulty for the doctor is to give the therapeutic options while remaining neutral regarding the choice. Hopefully, there are now clear, precise, and neutral tools to help in generating a mutually agreed decision.”

Are patients sufficiently informed about therapeutic options and related side effects?

Mrs C.: “Unfortunately, they are not. By knowing the options and related side effects, the patient has the choice. For example, a woman may be reluctant to gain weight but prefer to be a bit “tired” in the morning, whereas a man may prefer the opposite option. Some doctors can be reluctant to provide an exhaustive list of the side effects, but patients can easily have access to this information with the many internet forums and blogs available. In fact, the doctor is the most legitimate person to give a complete picture of the side effects, to give details on the existing solutions, and to clearly explain the benefit–risk balance that most of the patients ignore.

The expertise of the patient must be taken into account. It is important for patients to talk about their beliefs, preferences, values, and needs. Chronic patients are experienced. They often follow forums on the internet, they learn a lot about their disease and share their experience; it’s a collective intelligence. The patient becomes an expert in “living with”; it is important not to underestimate this expertise.”

What steps forward do you suggest?

Mrs C.: “First, training in SDM should be obligatory for all doctors; second, patients and the general public should receive more information about SDM.”

References

1. Nutt DJ, Kessler RC, Alonso J, Benbow A, Lecrubier Y, Lepine JP, et al. Consensus statement on the benefit to the community of ESEMeD (European Study of the Epidemiology of Mental Disorders) survey data on depression and anxiety. J Clin Psychiatry. 2007;68(Suppl 2):42–8.
2. Baghai TC, Moller HJ, Rupprecht R. Recent progress in pharmacological and non-pharmacological treatment options of major depression. Curr Pharm Des. 2006;12(4):503–15.

3. Farah WH, Alsawas M, Mainou M, Alahdab F, Farah MH, Ahmed AT, et al. Non-pharmacological treatment of depression: a systematic review and evidence map. Evid Based Med. 2016;21(6):214–21.

4. Fournier JC, DeRubeis RJ, Hollon SD, Dimidjian S, Amsterdam JD, Shelton RC, et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA. 2010;303(1):47–53.

5. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson BT. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration. PLoS Med. 2008;5(2):e45.

6. Sansone RA, Sansone LA. Antidepressant adherence: are patients taking their medications? Innov Clin Neurosci. 2012;9(5–6):41–6.

7. Blier P, Keller MB, Pollack MH, Thase ME, Zajecka JM, Dunn DL. Preventing recurrent depression: long-term treatment for major depressive disorder. J Clin Psychiatry. 2007;68(3):e06.

8. Kennedy S, McIntyre R, Fallu A, Lam R. Pharmacotherapy to sustain the fully remitted state. J Psychiatry Neurosci. 2002;27(4):269–80.

9. Melfi CA, Chawla AJ, Croghan TW, Hanna MP, Kennedy S, Sredl K. The effects of adherence to antidepressant treatment guidelines on relapse and recurrence of depression. Arch Gen Psychiatry. 1998;55(12):1128–32.

10. Paykel ES. Continuation and maintenance therapy in depression. Br Med Bull. 2001;57:145–59.

11. Fagot JP, Cuerq A, Samson S, Fogot-Campagna A. Cohort of one million patients initiating antidepressant treatment in France: 12-month follow-up. Int J Clin Pract. 2016;70(9):744–51.

12. Olsson M, Marcus SC, Tedeschi M, Wan GJ. Continuity of antidepressant treatment for adults with depression in the United States. Am J Psychiatry. 2006;163(1):101–8.

13. Aikens JE, Nease DE Jr, Nau DP, Klinkman MS, Schwenk TL. Adherence to maintenance-phase antidepressant medication as a function of patient beliefs about medication. Ann Fam Med. 2005;3(1):23–30.

14. Aikens JE, Nease DE Jr, Klinkman MS. Explaining patients’ beliefs about the necessity and harmfulness of antidepressants. Ann Fam Med. 2008;6(1):23–9.

15. Malhi GS, Basset D, Boyce P, Bryant R, Fitzgerald PB, Fritz K, et al. Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. Aust N Z J Psychiatry. 2015;49(12):1087–206.

16. Davies NM, Gunnell D, Thomas KH, Metcalfe C, Windmeijer F, Martin RM. Physicians’ prescribing preferences were a potential instrument for patients’ actual prescriptions of antidepressants. J Clin Epidemiol. 2013;66(12):1386–96.

17. Gaismaier W, Anderson BL, Schukin J. How do physicians provide statistical information about antidepressants to hypnotical patients? Med Decis Mak. 2014;34(2):206–15.

18. Mann JJ. The medical management of depression. N Engl J Med. 2005;353(17):1819–34.

19. Legare F, Turcotte S, Stacey D, Ratte S, Kryworuchko J, Graham ID. Patients’ perceptions of sharing in decisions: a systematic review of interventions to enhance shared decision making in routine clinical practice. Patient. 2012;5(1):1–19.

20. Zimmerman M, McGlinchey JB, Posternak MA, Friedman M, Attiullah N, Boerscu D. How should remission from depression be defined? The depressed patient’s perspective. Am J Psychiatry. 2006;163(1):148–50.

21. Rokke PD, Tomhave JA, Jocic Z. The role of client choice and target selection in self-management therapy for depression in older adults. Psychol Aging. 1999;14(1):155–69.

22. Bull SA, Hu XH, Hunkeler EM, Lee JY, Ming EE, Markson LE, et al. Discontinuation of use and switching of antidepressants: influence of patient-physician communication. JAMA. 2002;288(11):1403–9.

23. Loh A, Simon D, Wills CE, Kriston L, Niebling W, Harter M. The effects of a shared decision-making intervention in primary care of depression: a cluster-randomized controlled trial. Patient Educ Couns. 2007;67(3):324–32.

24. Charles C, Gafni A, Whelan T. Decision-making in the physician-patient encounter: revisiting the shared treatment decision-making model. Soc Sci Med. 1999;49(5):651–61.

25. Coulter A, Collins A. Making shared decision-making a reality. No decision about me, without me. London: King’s Fund; 2011.

26. Slade M. Implementing shared decision making in routine mental health care. World Psychiatry. 2017;16(2):146–53.

27. Ozanne EM, Kler JP, Esserman LJ. Breast cancer risk assessment and prevention: a framework for shared decision-making consultations. Breast J. 2006;12(2):103–13.

28. Kiesler DJ, Auerbach SM. Integrating measurement of control and affiliation in studies of physician–patient interaction: the interpersonal circumplex. Soc Sci Med. 2003;57(9):1707–22.

29. Mead N, Bower P. Patient-centredness: a conceptual framework and review of the empirical literature. Soc Sci Med. 2000;51(7):1087–110.

30. Greenfield S, Kaplan SH, Ware JE Jr, Yano EM, Frank HJ. Patients’ participation in medical care: effects on blood sugar control and quality of life in diabetes. J Gen Intern Med. 1995;10(1):5–9.

31. Hamann J, Leucht S, Kissling W. Shared decision making in psychiatry. Acta Psychiatr Scand. 2003;107(6):403–9.

32. Hamann J, Langer B, Winkler V, Busch R, Cohen R, Leucht S, et al. Shared decision making for in-patients with schizophrenia. Acta Psychiatr Scand. 2006;114(4):265–73.

33. Hauser K, Koerler A, Kuhr K, Albus C, Herzig S, Matthes J. Outcome-relevant effects of shared decision making. Dtsch Arztebl Int. 2015;112(40):665–71.

34. O’Connor AM, Drake ER, Wells GA, Tugwell P, Laupacis A, Elmslie T. A survey of the decision-making needs of Canadians faced with complex health decisions. Health Expect. 2003;6(2):97–109.

35. Clever SL, Ford DE, Rubenstein LV, Rost KM, Meredith LS, Sherbourne CD, et al. Primary care patients’ involvement in decision-making is associated with improvement in depression. Med Care. 2006;44(5):398–405.

36. Duncan E, Best C, Hagen S. Shared decision making interventions for people with mental health conditions. Cochrane Database Syst Rev. 2010;1:CD007297.

37. Tiacht L, Wusten C, Daubmann A, Lieberher S, Harter M, Diemer J. Information and decision-making needs among people with mental disorders: a systematic review of the literature. Health Expect. 2015;18(6):1856–72.

38. Adams JR, Drake RE. Shared decision-making and evidence-based practice. Community Ment Health J. 2006;42(1):87–105.

39. Patel SR, Bakken S, Ruland C. Recent advances in shared decision-making for mental health. Curr Opin Psychiatry. 2008;21(6):606–12.

40. Schauer C, Everett A, Del Vecchio P, Anderson L. Promoting the value and practice of shared decision-making in mental health care. Psychiatr Rehabil J. 2007;31(1):54–61.

41. Simon D, Schorr G, Wirtz M, Vodermaier A, Caspari C, Neuher J, et al. Development and first validation of the shared treatment decision-making questionnaire (SDM-Q). Patient Educ Couns. 2008;63(3):319–27.

42. Wills CE, Holmes-Rovner M. Integrating decision making and mental health interventions research: research directions. Clin Psychol (New York). 2006;13(1):9–25.
43. Joosten EA, DeFuentes-Merillas L, de Weert GH, Sensky T, van der Staa CP, de Jong CA. Systematic review of the effects of shared decision-making on patient satisfaction, treatment adherence and health status. Psychother Psychosom. 2008;77(4):219–26.

44. Ludman E, Katon W, Bush T, Rutter C, Lin E, Simon G, et al. Behavioural factors associated with symptom outcomes in a primary care-based depression prevention intervention trial. Psychol Med. 2003;33(6):1061–70.

45. Joosten EA, de Jong CA, de Weert-van Oene GH, Sensky T, van der Staa CP. Shared decision-making reduces drug use and psychiatric severity in substance-dependent patients. Psychother Psychosom. 2009;78(4):245–53.

46. Joosten EA, de Jong CA, de Weert-van Oene GH, Sensky T, van der Staa CP. Shared decision-making: increases autonomy in substance-dependent patients. Subst Use Misuse. 2011;46(8):1037–8.

47. Samalin L, Genty JB, Boyer L, Lopez-Castroman J, Abbar M, Llorca PM. Shared decision-making: a systematic review focusing on mood disorders. Curr Psychiatry Rep. 2018;20(4):23.

48. Bauer AM, Parker MM, Schilling D, Katon W, Adler N, Adams AS, et al. Associations between antidepressant adherence and shared decision-making, patient-provider trust, and communication among adults with diabetes: diabetes study of Northern California (DISTANCE). J Gen Intern Med. 2014;29(8):1139–47.

49. Thompson L, McCabe R. The effect of clinician-patient alliance and communication on treatment adherence in mental health care: a systematic review. BMC Psychiatry. 2012;12(4):87.

50. Degner LF, Horschuc M, Boyer L, de Chazeron J, Blanc O, Abbar M, et al. Efficacy of shared decision-making on treatment adherence of patients with bipolar disorder: a cluster randomized trial (ShareD-BD). BMC Psychiatry. 2018;18(1):103.

51. Hamann J, Neuner B, Kasper J, Vordermaier A, Loh A, Deinzer A, et al. Participation preferences of patients with acute and chronic conditions. Health Expect. 2007;10(4):358–63.

52. Hamann J, Kohl S, McCabe R, Buhner M, Mendel R, Albus M, et al. What can patients do to facilitate shared decision making? A qualitative study of patients with depression or schizophrenia and psychiatrists. Soc Psychiatry Psychiatr Epidemiol. 2016;51(4):617–25.

53. Beisecker AE, Beisecker TD. Patient information-seeking behaviors when communicating with doctors. Med Care. 1990;28(1):19–28.

54. Degner LF, Kristjanson LJ, Bowman D, Sloan JA, Carriere KC, O’Neil J, et al. Information needs and decisional preferences in women with breast cancer. JAMA. 1997;277(18):1485–92.

55. Wills CE, Holmes-Rovner M. Preliminary validation of the Satisfaction With Decision scale with depressed primary care patients. Health Expect. 2003;6(2):149–59.

56. Arora NK, McHorney CA. Patient preferences for medical decision-making: who really wants to participate? Med Care. 2000;38(3):335–41.

57. Adams JR, Drake RE, Wolford GL. Shared decision-making preferences of people with severe mental illness. Psychiatr Serv. 2007;58(9):1219–21.

58. Deegan PE, Rapp C, Holter M, Riefer M. Best practices: a program to support shared decision making in an outpatient psychiatric medication clinic. Psychiatr Serv. 2008;59(6):603–5.

59. Makoul G, Clayman ML. An integrative model of shared decision making in medical encounters. Patient Educ Couns. 2006;60(3):301–12.

60. Young HN, Bell RA, Epstein RM, Feldman MD, Kravitz RL. Physicians’ shared decision-making behaviors in depression care. Arch Intern Med. 2008;168(13):1404–8.

61. LeBlanc A, Herrin J, Williams MD, Inselman JW, Branda ME, Shah ND, et al. Shared decision making for antidepressants in primary care: a cluster randomized trial. JAMA Intern Med. 2015;175(11):1761–70.

62. Menea M, Garvelink MM, Adekpédjou R, Perez MM, Robitaille H, Turcotte S, et al. Factors associated with shared decision making among primary care physicians: findings from a multicentre cross-sectional study. Health Expect. 2018;21(1):212–21.

63. Sanders AR, Bensing JM, Essed MA, Magnee T, de Wit NJ, Verhaak PF. Does training general practitioners result in more shared decision making during consultations? Patient Educ Couns. 2017;100(3):563–74.

64. Benbassat J, Pilpel D, Tidhar M. Patients’ preferences for participation in clinical decision making: a review of published surveys. Behav Med. 1998;24(2):81–8.

65. Degner LF, Sloan JA. Decision making during serious illness: what role do patients really want to play? J Clin Epidemiol. 1992;45(9):941–50.

66. Rosen P, Anell A, Hjortberg C. Patient views on choice and participation in primary health care. Health Policy. 2001;55(2):121–8.

67. Solberg LI, Crain AL, Rubenstein L, Unutzer J, Whitebird RR, Beck A. How much shared decision making occurs in usual primary care of depression? J Am Board Fam Med. 2014;27(2):199–208.

68. Hamann J, Maris N, Ioshidou P, Mendel R, Cohen R, Wolf P, et al. Effects of a question prompt sheet on active patient behaviour: a randomized controlled trial with depressed outpatients. Int J Soc Psychiatry. 2014;60(3):227–35.

69. Hargraves I, LeBlanc A, Shah ND, Montori VM. Shared decision-making: the need for patient-physician conversation, not just information. Health Aff (Millwood). 2016;35(4):627–9.

70. Weckbach S, Kocak T, Reichel H, Lattig F. A survey on patients’ knowledge and expectations during informed consent for spinal surgery: can we improve the shared decision-making process? Patient Saf Surg. 2016;10:15.

71. Elwyn G, Edwards A, Wensing M, Hood K, Atwell C, Grol R. Shared decision making: developing the OPTION scale for measuring patient involvement. Qual Saf Health Care. 2003;12(2):93–9.

72. de Las Cuevas C, Penate W, Perestelo-Perez L, Serrano-Aguilar P. Shared decision making in psychiatric practice and the primary care setting is unique, as measured using a 9-item Shared Decision Making Questionnaire (SDM-Q-9). Neuropsychiatr Dis Treat. 2013;9:1045–52.

73. Quirk A, Chaplin R, Lelliott P, Seale C. How pressure is applied to pressure patients’ preferences and perceived involvement in decision making during consultations? Patient Educ Couns. 2013;91(1):205–12.

74. Beers E, Lee NM, Johnson JT. The role of patients: shared decision making: the need for patient-clinician conversation, not just information. Health Aff (Millwood). 2016;35(4):627–9.

75. Elwyn G, Edwards A, Wensing M, Hood K, Atwell C, Grol R. Shared decision making: developing the OPTION scale for measuring patient involvement. Qual Saf Health Care. 2003;12(2):93–9.

76. Eliacin J, Salyers MP, Kukla M, Matthias MS. Factors influencing patients’ preferences and perceived involvement in shared decision-making in mental health care. J Ment Health. 2015;24(1):24–8.

77. Stiggelbout AM, Van der Weijden T, De Wit MP, Frosch D, Legare F, Montori VM, et al. Shared decision making: really putting patients at the centre of healthcare. BMJ. 2012;344:e256.

78. Brackett CD, Kearing S. Use of a web-based survey to facilitate shared decision making for patients eligible for cancer screening. Patient Saf Surg. 2016;10:15.

79. Stacey D, Legare F, Lyddiatt A, Giguere AM, Yoganathan M, et al. Shared decision making: really putting patients at the centre of healthcare. BMJ. 2012;344:e256.

80. Sanders AR, Bensing JM, Essed MA, Magnee T, de Wit NJ, Verhaak PF. Does training general practitioners result in more shared decision making during consultations? Patient Educ Couns. 2017;100(3):563–74.
80. Agoritsas T, Heen AF, Brandt L, Alonso-Coello P, Kristiansen A, Akl EA, et al. Decision aids that really promote shared decision making: the pace quickens. BMJ. 2015;10(350):g7624.

81. Stacey D, Legare F, Col NF, Bennett CL, Barry MJ, Eden KB, et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst Rev. 2014;1:CD001431.
Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:
Hopwood, M

Title:
The Shared Decision-Making Process in the Pharmacological Management of Depression

Date:
2020-02-01

Citation:
Hopwood, M. (2020). The Shared Decision-Making Process in the Pharmacological Management of Depression. PATIENT-PATIENT CENTERED OUTCOMES RESEARCH, 13 (1), pp.23-30. https://doi.org/10.1007/s40271-019-00383-w.

Persistent Link:
http://hdl.handle.net/11343/246985

File Description:
published version

License:
CC BY-NC